Base de dados : MEDLINE Pesquisa : D02.033.415.510.500.303 [Categoria DeCS] Referências encontradas : 248 [refinar] Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 25

ir para página

1 / 248

MEDLINE

seleciona para imprimir Fotocópia Texto completo

[PMID]: 29024883 [Au] Autor: Sopilniak A; Elkayam R; Rossin AV; Lev O [Ad] Endereço: Casali Center of Applied Chemistry, The Institute of Chemistry, The Hebrew University of Jerusalem, Jerusalem 9190401, Israel. [Ti] Título: Emerging organic pollutants in the vadose zone of a soil aquifer treatment system: Pore water extraction using positive displacement. [So] Source: Chemosphere;190:383-392, 2018 Jan. [Is] ISSN: 1879-1298 [Cp] País de publicação: England [La] Idioma: eng [Ab] Resumo: Trace organic compounds in effluents, water streams and aquifers are amply reported. However, the mobile pool of Emerging Organic Contaminants (EOCs) in the deep parts of the vadose zone is hard to estimate, due to difficulties in extraction of sufficient quantity of pore water. Here, we present a new methodology for depth profiling of EOCs in pore water by Positive Displacement Extraction (PDE): Pore water extraction from unsaturated soil samples is carried out by withdrawal of soil cores by direct-push drilling and infiltrating the core by organics free water. We show that EOC concentrations in the water eluted in the plateau region of the inverse breakthrough curve is equal to their pore water concentrations. The method was previously validated for DOC extraction, and here the scope of the methodology is extended to pore water extraction for organic pollutants analysis. Method characteristics and validation were carried out with atrazine, simazine, carbamazepine, venlafaxine, O-desmethylvenlafaxine and caffeine in the concentration range of several ng to several µg/liter. Validation was carried out by laboratory experiments on three different soils (sandy, sandy-clayey and clayey). Field studies in the vadose zone of a SAT system provided 27 m deep EOC profiles with less than 1.5 m spatial resolution. During the percolation treatment, carbamazepine remained persistent, while the other studied EOCs were attenuated to the extent of 50-99%.The highest degradation rate of all studied EOCs was in the aerobic zone. EOC levels based on PDE and extraction by centrifugation were compared, showing a positive bias for centrifugation. [Mh] Termos MeSH primário: Água Subterrânea/análise Poluentes do Solo/análise Extração em Fase Sólida/métodos Poluentes Químicos da Água/análise [Mh] Termos MeSH secundário: Atrazina/análise Carbamazepina/análise Succinato de Desvenlafaxina/análise Métodos Compostos Orgânicos/análise Simazina Solo/química Água/análise [Pt] Tipo de publicação: JOURNAL ARTICLE [Nm] Nome de substância: 0 (Organic Chemicals); 0 (Soil); 0 (Soil Pollutants); 0 (Water Pollutants, Chemical); 059QF0KO0R (Water); 33CM23913M (Carbamazepine); QJA9M5H4IM (Atrazine); SG0C34SMY3 (Simazine); ZB22ENF0XR (Desvenlafaxine Succinate) [Em] Mês de entrada: 1802 [Cu] Atualização por classe: 180228 [Lr] Data última revisão: 180228 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 171013 [St] Status: MEDLINE

2 / 248

MEDLINE

seleciona para imprimir Fotocópia Texto completo

[PMID]: 28146000 [Au] Autor: Mosca D; Zhang M; Prieto R; Boucher M [Ad] Endereço: From the *Alvear Emergency Psychiatric Hospital, Buenos Aires, Argentina; †Pfizer Inc, La Jolla, CA; ‡Pfizer GEP, SLU, Madrid, Spain; and §Pfizer Canada Inc, Kirkland, Quebec, Canada. [Ti] Título: Efficacy of Desvenlafaxine Compared With Placebo in Major Depressive Disorder Patients by Age Group and Severity of Depression at Baseline. [So] Source: J Clin Psychopharmacol;37(2):182-192, 2017 Apr. [Is] ISSN: 1533-712X [Cp] País de publicação: United States [La] Idioma: eng [Ab] Resumo: PURPOSE: This post hoc meta-analysis evaluated the efficacy and safety of desvenlafaxine 50 and 100 mg versus placebo across age groups and severity of depression at baseline in patients with major depressive disorder. METHODS: Data from placebo and desvenlafaxine 50-mg and 100-mg dose arms were pooled from 9 short-term, placebo-controlled, major depressive disorder studies (N = 4279). Effects of age (18-40 years, >40 to <55 years, 55-<65 years, and ≥65 years) and baseline depression severity (mild, 17-item Hamilton Rating Scale for Depression total score [HAM-D17] ≤18; moderate, HAM-D17 >18 to <25; severe, HAM-D17 ≥25) on desvenlafaxine efficacy were assessed using analysis of covariance for continuous end points and logistic regression for categorical end points. FINDINGS: Desvenlafaxine-treated (50 or 100 mg/d) patients had significantly (P < 0.05, 2-sided) greater improvement in most measures of depression and function compared with placebo for patients 18 to 40 years, older than 40 to younger than 55 years, and 55 to younger than 65 years, with no significant evidence of an effect of age. Desvenlafaxine significantly improved most measures of depression and function in moderately and severely depressed patients. There was a significant baseline severity by treatment interaction for HAM-D17 total score only (P = 0.027), with a larger treatment effect for the severely depressed group. IMPLICATIONS: Desvenlafaxine significantly improved depressive symptoms in patients younger than 65 years and in patients with moderate or severe baseline depression. Sample sizes were not adequate to assess desvenlafaxine efficacy in patients 65 years or older or with mild baseline depression. [Mh] Termos MeSH primário: Ensaios Clínicos Controlados como Assunto/estatística & dados numéricos Transtorno Depressivo Maior/tratamento farmacológico Succinato de Desvenlafaxina/farmacologia Avaliação de Resultados (Cuidados de Saúde)/estatística & dados numéricos Inibidores da Recaptação de Serotonina e Norepinefrina/farmacologia Índice de Gravidade de Doença [Mh] Termos MeSH secundário: Adolescente Adulto Fatores Etários Idoso Succinato de Desvenlafaxina/administração & dosagem Succinato de Desvenlafaxina/efeitos adversos Feminino Seres Humanos Masculino Meia-Idade Inibidores da Recaptação de Serotonina e Norepinefrina/administração & dosagem Inibidores da Recaptação de Serotonina e Norepinefrina/efeitos adversos Adulto Jovem [Pt] Tipo de publicação: JOURNAL ARTICLE; META-ANALYSIS [Nm] Nome de substância: 0 (Serotonin and Noradrenaline Reuptake Inhibitors); ZB22ENF0XR (Desvenlafaxine Succinate) [Em] Mês de entrada: 1706 [Cu] Atualização por classe: 170626 [Lr] Data última revisão: 170626 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 170202 [St] Status: MEDLINE [do] DOI: 10.1097/JCP.0000000000000674

3 / 248

MEDLINE

seleciona para imprimir Fotocópia Texto completo

[PMID]: 27622824 [Au] Autor: Cooper JM; Brown JA; Cairns R; Isbister GK [Ad] Endereço: a Clinical Toxicology Research Group , University of Newcastle , Newcastle , Australia. [Ti] Título: Desvenlafaxine overdose and the occurrence of serotonin toxicity, seizures and cardiovascular effects. [So] Source: Clin Toxicol (Phila);55(1):18-24, 2017 Jan. [Is] ISSN: 1556-9519 [Cp] País de publicação: England [La] Idioma: eng [Ab] Resumo: CONTEXT: Desvenlafaxine is used to treat major depression. Desvenlafaxine is also the active metabolite of venlafaxine. Venlafaxine overdose can cause serotonin toxicity, seizures and cardiovascular effects, but there is limited information on desvenlafaxine overdose. OBJECTIVE: We aimed at investigating the clinical effects and complications from desvenlafaxine overdose. MATERIALS AND METHODS: This was a retrospective observational study of desvenlafaxine overdoses over a six-year period. Demographic details, dose and timing of the overdose, together with clinical effects, treatment and complications were extracted from a local hospital network database or the medical records of patients following hospital admission with a desvenlafaxine overdose. RESULTS: There were 182 cases of desvenlafaxine overdose included in the study. From the 182 cases, 75 were desvenlafaxine (± alcohol) only ingestions and 107 included one or more co-ingested drugs. In single-agent desvenlafaxine ingestions, median age was 25 years (range: 13-68 years) with a median ingested dose of 800 mg (range: 250-3500 mg; interquartile range (IQR): 600-1400 mg), and 54/75 (72%) were female. The Glasgow Coma Score (GCS) was 15 in 68/74 (92%) patients, 13-14 in 5/74 (7%), and was seven in one patient following aspiration. Mild hypertension (systolic blood pressure [BP] > 140-180 mmHg) occurred in 23/71 patients (32%), and tachycardia occurred in 29/74 (39%) patients. There were no abnormal QT intervals and no QRS >120 m s. Serotonin toxicity was diagnosed by the treating physician in 7/75 (9%) patients, but only one of these met the Hunter Serotonin Toxicity Criteria. None of the 75 patients who took desvenlafaxine only (± alcohol) had seizures, were admitted to intensive care or died. In comparison, the 107 patients taking desvenlafaxine in overdose with other medications developed more pronounced toxicity. Generalised seizures occurred in 5/107 (5%), but in three of these cases co-ingestants were possible proconvulsants. Fifteen patients had a GCS ≤9 and none had an abnormal QT or QRS. Severe effects appeared to be associated with coingestants. CONCLUSION: Desvenlafaxine overdose causes minor effects with mild hypertension and tachycardia. The risk of seizures or serotonin toxicity is low. [Mh] Termos MeSH primário: Antidepressivos/envenenamento Succinato de Desvenlafaxina/envenenamento Hipertensão/induzido quimicamente Convulsões/induzido quimicamente Taquicardia/induzido quimicamente [Mh] Termos MeSH secundário: Adolescente Adulto Idoso Overdose de Drogas Feminino Escala de Coma de Glasgow Seres Humanos Hipertensão/epidemiologia Masculino Meia-Idade Estudos Retrospectivos Convulsões/epidemiologia Taquicardia/epidemiologia Adulto Jovem [Pt] Tipo de publicação: JOURNAL ARTICLE; OBSERVATIONAL STUDY [Nm] Nome de substância: 0 (Antidepressive Agents); ZB22ENF0XR (Desvenlafaxine Succinate) [Em] Mês de entrada: 1703 [Cu] Atualização por classe: 170817 [Lr] Data última revisão: 170817 [Sb] Subgrupo de revista: AIM; IM [Da] Data de entrada para processamento: 160914 [St] Status: MEDLINE [do] DOI: 10.1080/15563650.2016.1223847

4 / 248

MEDLINE

seleciona para imprimir Fotocópia Texto completo

[PMID]: 27388659 [Au] Autor: Miranda LF; Domingues DS; Queiroz ME [Ad] Endereço: Departamento de Química, Faculdade de Filosofia Ciência e Letras de Ribeirão Preto, Universidade de São Paulo, P.O. Box 14040-901, Ribeirão Preto, SP, Brazil. [Ti] Título: Selective solid-phase extraction using molecularly imprinted polymers for analysis of venlafaxine, O-desmethylvenlafaxine, and N-desmethylvenlafaxine in plasma samples by liquid chromatography-tandem mass spectrometry. [So] Source: J Chromatogr A;1458:46-53, 2016 Aug 05. [Is] ISSN: 1873-3778 [Cp] País de publicação: Netherlands [La] Idioma: eng [Ab] Resumo: This paper focuses on the development of a novel miniaturized molecularly imprinted solid-phase extraction (MISPE) and ultra high performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) method to determine venlafaxine (VEN), O-desmethylvenlafaxine (ODV), and N-desmethylvenlafaxine (NDV) in plasma samples. The molecularly imprinted polymer (MIP) was prepared by the precipitation polymerization approach; VEN, metacrylic acid, ethylene glycol dimethacrylate, 2,2-azobisisobutyronitrile, and toluene were used as template, monomer, crosslinker, initiator, and porogen solvent, respectively. MIP and of the non-imprinted control polymer (NIP) sorbents were characterized by Fourier transform infrared spectroscopy and scanning electron microscopy. MIP phase presented higher extraction efficiency (MISPE, using plasma samples spiked with VEN) than the NIP phase (84 and 49% recovery rates, respectively). Analysis of other antidepressants with different chemical structures by MISPE-UHPLC-MS/MS attested to the selectivity of the developed MIP. The developed method presented precision assays with coefficients of variation (CV) smaller than 15%; accuracy assays with relative standard error (RSE%) values ranging from -12 to 16%, and linear ranges from 3 to 700ngmL(-1) for VEN, from 5 to 700ngmL(-1) for ODV, and from 3 to 500ngmL(-1) for NDV. The coefficients of determination (r(2)) were higher than 0.995. The lack-of-fit test also attested to the linearity of this method. This method was successfully applied to determine VEN, NDV, and ODV in plasma samples from depressed patients undergoing therapy with VEN. [Mh] Termos MeSH primário: Cicloexanóis/sangue Succinato de Desvenlafaxina/sangue Impressão Molecular Polímeros/química Extração em Fase Sólida/métodos Espectrometria de Massas em Tandem/métodos Cloridrato de Venlafaxina/sangue [Mh] Termos MeSH secundário: Acrilatos/química Antidepressivos/sangue Antidepressivos/química Antidepressivos/uso terapêutico Cromatografia Líquida de Alta Pressão Cicloexanóis/metabolismo Depressão/sangue Depressão/tratamento farmacológico Succinato de Desvenlafaxina/metabolismo Seres Humanos Metacrilatos/química Microscopia Eletrônica de Varredura Nitrilos/química Polimerização Espectroscopia de Infravermelho com Transformada de Fourier Tolueno/química Cloridrato de Venlafaxina/metabolismo Cloridrato de Venlafaxina/farmacocinética Cloridrato de Venlafaxina/uso terapêutico [Pt] Tipo de publicação: JOURNAL ARTICLE [Nm] Nome de substância: 0 (Acrylates); 0 (Antidepressive Agents); 0 (Cyclohexanols); 0 (Methacrylates); 0 (N-desmethylvenlafaxine); 0 (Nitriles); 0 (Polymers); 3FPU23BG52 (Toluene); 7BK5G69305 (ethylene dimethacrylate); 7D7RX5A8MO (Venlafaxine Hydrochloride); FZ6PX8U5YB (azobis(isobutyronitrile)); J94PBK7X8S (acrylic acid); ZB22ENF0XR (Desvenlafaxine Succinate) [Em] Mês de entrada: 1612 [Cu] Atualização por classe: 161230 [Lr] Data última revisão: 161230 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 160709 [St] Status: MEDLINE

5 / 248

MEDLINE

seleciona para imprimir Fotocópia

[PMID]: 27382725 [Au] Autor: Zong Y; Li J; Sun W; Liu G; Lu J; Shan G [Ti] Título: [Determination of succinic acid in desvenlafaxine succinate by high performance ion-exclusion chromatography and high performance ion-exchange chromatography]. [So] Source: Se Pu;34(2):189-93, 2016 Feb. [Is] ISSN: 1000-8713 [Cp] País de publicação: China [La] Idioma: chi [Ab] Resumo: New methods were developed for the determination of succinic acid in desvenlafaxine succinate (DVS) by high performance ion-exclusion chromatography (HPIEC) and high performance ion-exchange chromatography (HPIC). HPIEC and HPIC methods were used separately to determinate the succinic acid in DVS. With HPIEC, the sample was diluted with 2. 50 x 10(-3) mol/L sulfuric acid solution and filtrated by 0. 22 µm polyether sulfone filter membrane, and then analyzed by HPIEC directly without any further pretreatment. The analytical column was Phenomenex Rezex ROA-organic Acid H+(8%) (300 mmx7. 8 mm). The mobile phase was 2. 50x10(-3) mol/L sulfuric acid solution at the flow rate of 0. 5 mL/min. The column temperature was set at 40 °C, and the detection wavelength was 210 nm. The injection volume was 10 KL. The assay was quantified by external standard method. With HPIC, the sample was diluted with ultrapure water and filtrated by 0. 22 µm polyether sulfone filter membrane, and then analyzed by HPIC directly without any further pretreatment. The analytical column was Dionex IonPac AS11-HC (250 mm x 4 mm) with a guard column IonPacAG11-HC (50 mm x 4 mm). Isocratic KOH elute generator was used at the flow rate of 1. 0 mL/min. The detection was performed by a Dionex suppressed (DIONEX AERS 500 4-mm) conductivity detector. The injection volume was 10 µL. The content computation was performed with peak area external reference method. The results of HPIEC method for succinic acid were 28. 8%, 28. 9% and 28. 9%, while the results of HPIEC method were 28. 2%, 28. 6% and 28. 6%. The results of HPIEC and HPIC methods were not significantly different. The two methods can both be used to determine the contents of succinic acid in DVS. The surveillance analytical method should be chosen according to the situation. [Mh] Termos MeSH primário: Cromatografia por Troca Iônica Succinato de Desvenlafaxina/análise Ácido Succínico/análise [Mh] Termos MeSH secundário: Ácidos Cromatografia em Gel Soluções Ácidos Sulfúricos Água [Pt] Tipo de publicação: ENGLISH ABSTRACT; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T [Nm] Nome de substância: 0 (Acids); 0 (Solutions); 0 (Sulfuric Acids); 059QF0KO0R (Water); AB6MNQ6J6L (Succinic Acid); O40UQP6WCF (sulfuric acid); ZB22ENF0XR (Desvenlafaxine Succinate) [Em] Mês de entrada: 1607 [Cu] Atualização por classe: 161018 [Lr] Data última revisão: 161018 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 160708 [St] Status: MEDLINE

6 / 248

MEDLINE

seleciona para imprimir Fotocópia PubMed Central Texto completo

[PMID]: 27303005 [Au] Autor: Kaicker J; Bostwick J [Ad] Endereço: Emergency medicine resident in the Emergency Medicine Program at Western University in London, Ont. [Ti] Título: Co-ingestion of tricyclic antidepressants with selective norepinephrine reuptake inhibitors: Overdose in the emergency department. [So] Source: Can Fam Physician;62(6):485-9, 2016 Jun. [Is] ISSN: 1715-5258 [Cp] País de publicação: Canada [La] Idioma: eng [Mh] Termos MeSH primário: Amitriptilina/efeitos adversos Antidepressivos Tricíclicos/efeitos adversos Depressão/tratamento farmacológico Succinato de Desvenlafaxina/efeitos adversos Overdose de Drogas/diagnóstico Inibidores da Recaptação de Serotonina e Norepinefrina/efeitos adversos [Mh] Termos MeSH secundário: Adolescente Estado de Consciência/efeitos dos fármacos Overdose de Drogas/tratamento farmacológico Quimioterapia Combinada Eletrocardiografia Serviço Hospitalar de Emergência Feminino Escala de Coma de Glasgow Seres Humanos Hipotensão/induzido quimicamente Síndrome do QT Longo/induzido quimicamente Convulsões/induzido quimicamente [Pt] Tipo de publicação: CASE REPORTS; JOURNAL ARTICLE [Nm] Nome de substância: 0 (Antidepressive Agents, Tricyclic); 0 (Serotonin and Noradrenaline Reuptake Inhibitors); 1806D8D52K (Amitriptyline); ZB22ENF0XR (Desvenlafaxine Succinate) [Em] Mês de entrada: 1703 [Cu] Atualização por classe: 170817 [Lr] Data última revisão: 170817 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 160616 [St] Status: MEDLINE

7 / 248

MEDLINE

seleciona para imprimir Fotocópia Texto completo

[PMID]: 27280963 [Au] Autor: Lam RW; Iverson GL; Evans VC; Yatham LN; Stewart K; Tam EM; Axler A; Woo C [Ad] Endereço: Department of Psychiatry, University of British Columbia, Mood Disorders Centre of Excellence, Djavad Mowafaghian Centre for Brain Health, Canada. Electronic address: r.lam@ubc.ca. [Ti] Título: The effects of desvenlafaxine on neurocognitive and work functioning in employed outpatients with major depressive disorder. [So] Source: J Affect Disord;203:55-61, 2016 Oct. [Is] ISSN: 1573-2517 [Cp] País de publicação: Netherlands [La] Idioma: eng [Ab] Resumo: BACKGROUND: Major depressive disorder (MDD) is associated with staggering personal and economic costs, a major proportion of which stem from impaired psychosocial and occupational functioning. Few studies have examined the impact of depression-related cognitive dysfunction on work functioning. We examined the association between neurocognitive and work functioning in employed patients with MDD. METHODS: Employed adult outpatients (n=36) with MDD of at least moderate severity (≥23 on the Montgomery Asberg Depression Rating Scale, MADRS) and subjective cognitive complaints completed neurocognitive tests (CNS Vital Signs computerized battery) and validated self-reports of their work functioning (LEAPS, HPQ) before and after 8 weeks of open-label treatment with flexibly-dosed desvenlafaxine 50-100mg/day. Relationships between neurocognitive tests and functional measures were examined using bivariate correlational and multiple regression analyses, as appropriate. An ANCOVA model examined whether significant change in neurocognitive performance, defined as improvement of ≥1SD in the Neurocognition Index (NCI) from baseline to post-treatment, was associated with improved outcomes. RESULTS: Patients showed significant improvements in depressive symptom, neurocognitive, and work functioning measures following treatment with desvenlafaxine (e.g., MADRS response=77% and MADRS remission=49%). There were no significant correlations between changes in NCI or cognitive domain subscales and changes in MADRS, LEAPS, or HPQ scores. However, patients demonstrating significant improvement in NCI scores (n=11, 29%) had significantly greater improvement in clinical and work functioning outcomes compared to those without NCI improvement. LIMITATIONS: The limitations of this study include small sample size, lack of a placebo control group, and lack of a healthy comparison group. Our sample also had more years of education and higher premorbid intelligence than the general population. CONCLUSIONS: There were no significant correlations between changes in neurocognitive and work functioning measures in this study. However, meaningful improvement in neurocognitive functioning with desvenlafaxine was associated with greater improvement in both mood and occupational outcomes. This suggests that addressing cognitive dysfunction may improve clinical and occupational outcomes in employed patients with MDD. However, the relationship between neurocognitive and work functioning in MDD is complex and requires further study. [Mh] Termos MeSH primário: Antidepressivos/farmacologia Cognição/efeitos dos fármacos Transtorno Depressivo Maior/tratamento farmacológico Succinato de Desvenlafaxina/farmacologia Emprego/psicologia [Mh] Termos MeSH secundário: Adulto Antidepressivos/uso terapêutico Transtorno Depressivo Maior/diagnóstico Transtorno Depressivo Maior/psicologia Succinato de Desvenlafaxina/uso terapêutico Esquema de Medicação Feminino Seres Humanos Masculino Meia-Idade Testes Neuropsicológicos Saúde do Trabalhador Escalas de Graduação Psiquiátrica Autorrelato Resultado do Tratamento [Pt] Tipo de publicação: CLINICAL TRIAL; JOURNAL ARTICLE [Nm] Nome de substância: 0 (Antidepressive Agents); ZB22ENF0XR (Desvenlafaxine Succinate) [Em] Mês de entrada: 1711 [Cu] Atualização por classe: 171102 [Lr] Data última revisão: 171102 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 160610 [St] Status: MEDLINE

8 / 248

MEDLINE

seleciona para imprimir Fotocópia PubMed Central Texto completo Texto completo SciELO Brasil

[PMID]: 27240293 [Au] Autor: Xu Y; Bai SJ; Lan XH; Qin B; Huang T; Xie P [Ad] Endereço: Department of Neurology, Yongchuan Hospital, Chongqing Medical University, Chongqing, China. [Ti] Título: Randomized controlled trials of serotonin-norepinephrine reuptake inhibitor in treating major depressive disorder in children and adolescents: a meta-analysis of efficacy and acceptability. [So] Source: Braz J Med Biol Res;49(6), 2016 May 24. [Is] ISSN: 1414-431X [Cp] País de publicação: Brazil [La] Idioma: eng [Ab] Resumo: New generation antidepressant therapies, including serotonin-norepinephrine reuptake inhibitor (SNRIs), were introduced in the late 1980s; however, few comprehensive studies have compared the benefits and risks of various contemporary treatments for major depressive disorder (MDD) in young patients. A comprehensive literature search of PubMed, Cochrane, Embase, Web of Science, and PsycINFO databases was conducted from 1970 to January 2015. Only clinical trials that randomly assigned one SNRI or placebo to patients aged 7 to 18 years who met the diagnostic criteria for major depressive disorder were included. Treatment success, dropout rate, and suicidal ideation/attempt outcomes were measured. Primary efficacy was determined by pooling the risk ratios (RRs) of treatment response and remission. Acceptability was determined by pooling the RRs of dropouts for all reasons and for adverse effects as well as suicide-risk outcomes. Five trials with a total of 973 patients were included. SNRIs were not significantly more effective than placebo for treatment response but were for remission. The comparison of patients taking SNRIs that dropped out for all reasons and those taking placebo did not reach statistical significance. Significantly more patients taking SNRIs dropped out for adverse effects than those taking placebo. No significant difference was found in suicide-related risk outcomes. SNRI therapy does not display a superior efficacy and is not better tolerated compared to placebo in these young patients. However, duloxetine has a potential beneficial effect for depression in young populations, showing a need for further research. [Mh] Termos MeSH primário: Antidepressivos/uso terapêutico Transtorno Depressivo Maior/tratamento farmacológico Ensaios Clínicos Controlados Aleatórios como Assunto Inibidores da Recaptação de Serotonina e Norepinefrina/uso terapêutico [Mh] Termos MeSH secundário: Adolescente Criança Ciclopropanos/uso terapêutico Succinato de Desvenlafaxina/uso terapêutico Cloridrato de Duloxetina/uso terapêutico Feminino Seres Humanos Masculino Placebos/uso terapêutico Resultado do Tratamento Cloridrato de Venlafaxina/uso terapêutico [Pt] Tipo de publicação: JOURNAL ARTICLE; META-ANALYSIS; REVIEW [Nm] Nome de substância: 0 (Antidepressive Agents); 0 (Cyclopropanes); 0 (Placebos); 0 (Serotonin and Noradrenaline Reuptake Inhibitors); 7D7RX5A8MO (Venlafaxine Hydrochloride); 9044SC542W (Duloxetine Hydrochloride); G56VK1HF36 (milnacipran); ZB22ENF0XR (Desvenlafaxine Succinate) [Em] Mês de entrada: 1701 [Cu] Atualização por classe: 170220 [Lr] Data última revisão: 170220 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 160531 [St] Status: MEDLINE

9 / 248

MEDLINE

seleciona para imprimir Fotocópia

[PMID]: 27099215 [Au] Autor: Martín-Larrégola M; Gómez-Arnau J; Rodríguez-Salgado B; Dolengevich-Segal H [Ad] Endereço: Servicio de Psiquiatría. Hospital Universitario del Henares, Coslada, Madrid. [Ti] Título: Combined use of desvenlafaxine and electroconvulsive therapy. [So] Source: Actas Esp Psiquiatr;44(2):79-82, 2016 Mar-Apr. [Is] ISSN: 1578-2735 [Cp] País de publicação: Spain [La] Idioma: eng [Mh] Termos MeSH primário: Antidepressivos/uso terapêutico Transtorno Depressivo Maior/terapia Succinato de Desvenlafaxina/uso terapêutico Eletroconvulsoterapia [Mh] Termos MeSH secundário: Transtorno Depressivo Maior/tratamento farmacológico Seres Humanos Resultado do Tratamento [Pt] Tipo de publicação: LETTER [Nm] Nome de substância: 0 (Antidepressive Agents); ZB22ENF0XR (Desvenlafaxine Succinate) [Em] Mês de entrada: 1709 [Cu] Atualização por classe: 170906 [Lr] Data última revisão: 170906 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 160422 [St] Status: MEDLINE

10 / 248

MEDLINE

seleciona para imprimir Fotocópia

[PMID]: 27023264 [Au] Autor: Ng CH; Bousman C; Smith DJ; Dowling N; Byron K; King J; Sarris J [Ad] Endereço: Professorial Unit, The Melbourne Clinic, Department of Psychiatry, University of Melbourne. [Ti] Título: A Prospective Study of Serotonin and Norepinephrine Transporter Genes and the Response to Desvenlafaxine Over 8 Weeks in Major Depressive Disorder. [So] Source: Pharmacopsychiatry;49(5):210-212, 2016 Sep. [Is] ISSN: 1439-0795 [Cp] País de publicação: Germany [La] Idioma: eng [Ab] Resumo: No studies to date have evaluated and genetic polymorphisms influencing antidepressant response to desvenlafaxine. We conducted an 8-week, open-label, prospective pilot study in 35 patients with major depressive disorder to assess the effects of genetic variations in SLC6A2 and SLC6A4 on both efficacy and side effect profile of desvenlafaxine. Results revealed that homozygotes for the HTTLPR allele showed a 33% HDRS reduction compared to a 58% reduction for L allele carriers (p=0.037). No results survived adjustments for covariates or multiple comparisons. While these results need to be interpreted cautiously, they provide preliminary support for the HTTLPR polymorphism as potential modifier of desvenlafaxine efficacy. [Mh] Termos MeSH primário: Antidepressivos/uso terapêutico Transtorno Depressivo Maior/tratamento farmacológico Transtorno Depressivo Maior/genética Succinato de Desvenlafaxina/uso terapêutico Proteínas da Membrana Plasmática de Transporte de Norepinefrina/genética Farmacogenética Polimorfismo de Nucleotídeo Único/genética Proteínas da Membrana Plasmática de Transporte de Serotonina/genética [Mh] Termos MeSH secundário: Adulto Feminino Seres Humanos Masculino Meia-Idade Proteínas da Membrana Plasmática de Transporte de Norepinefrina/metabolismo Projetos Piloto Estudos Prospectivos Proteínas da Membrana Plasmática de Transporte de Serotonina/metabolismo [Pt] Tipo de publicação: JOURNAL ARTICLE [Nm] Nome de substância: 0 (Antidepressive Agents); 0 (Norepinephrine Plasma Membrane Transport Proteins); 0 (Serotonin Plasma Membrane Transport Proteins); ZB22ENF0XR (Desvenlafaxine Succinate) [Em] Mês de entrada: 1703 [Cu] Atualização por classe: 170306 [Lr] Data última revisão: 170306 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 160330 [St] Status: MEDLINE

---

página 1 de 25

ir para página

Refinar a pesquisa

Base de dados : MEDLINE

Formulário avançado

		Pesquisar	no campo
1			PalavrasDescritor de assuntoDescritor de assunto primárioLimitesAutorPalavras do títuloPalavras do resumoIdiomaPaís de publicaçãoNome de substânciaNome de pessoa como assuntoRevistaAssunto de RevistaISSNTipo de publicaçãoIdentificador únicoMês de entradaAno de publicaçãoTexto completoAtualização por classeCategoria DeCSCategoria DeCS explodidaCategoria CID-10SubSetsPais de AfiliaçãoAfiliaçãoAfiliação 2
2	and or and not		PalavrasDescritor de assuntoDescritor de assunto primárioLimitesAutorPalavras do títuloPalavras do resumoIdiomaPaís de publicaçãoNome de substânciaNome de pessoa como assuntoRevistaAssunto de RevistaISSNTipo de publicaçãoIdentificador únicoMês de entradaAno de publicaçãoTexto completoAtualização por classeCategoria DeCSCategoria DeCS explodidaCategoria CID-10SubSetsPais de AfiliaçãoAfiliaçãoAfiliação 2
3	and or and not		PalavrasDescritor de assuntoDescritor de assunto primárioLimitesAutorPalavras do títuloPalavras do resumoIdiomaPaís de publicaçãoNome de substânciaNome de pessoa como assuntoRevistaAssunto de RevistaISSNTipo de publicaçãoIdentificador únicoMês de entradaAno de publicaçãoTexto completoAtualização por classeCategoria DeCSCategoria DeCS explodidaCategoria CID-10SubSetsPais de AfiliaçãoAfiliaçãoAfiliação 2

Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde